Overview

• Atossa Therapeutics Q3 net loss widens to $8.7 mln, operating expenses rise to $9.3 mln

• Company advances $(Z)$-endoxifen program with regulatory strategies and clinical trials

• Appointed key leadership roles to drive (Z)-endoxifen development and commercialization and streamline development programs

Outlook

• Atossa targets IND submission for (Z)-endoxifen in Q4 2025

• Company plans to update shareholders on FDA meeting outcome by year-end 2025

• Atossa focuses on NDA-enabling activities for (Z)-endoxifen in 2026

Result Drivers

• R&D EXPENSES - Increased R&D expenses due to higher spending on (Z)-endoxifen trials and drug development costs

• REGULATORY STRATEGY - Co requested a Type C meeting with FDA to accelerate (Z)-endoxifen development for breast cancer risk reduction

• TRIAL STREAMLINING - Streamlined EVANGELINE breast cancer trial to focus on NDA-enabling activities and reduce costs

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Atossa Therapeutics Inc is $5.50, about 85% above its November 11 closing price of $0.83

Press Release: ID:nPnBF91Za

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)